BDBM108096 US8598206, Table 6, 5
SMILES: CC(=O)N1CCC(CC[C@@H](NS(=O)(=O)Cc2ccccc2)C(=O)N[C@@H](CCC2CCNCC2)C(=O)NCc2ccc(cc2)C(N)=N)CC1
InChI Key: InChIKey=XATHBXYKVIAZOR-AJQTZOPKSA-N
Data: 11 KI
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Plasminogen (Homo sapiens (Human)) | BDBM108096 (US8598206, Table 6, 5) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 1.80 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
The Medicines Company (Leipzig) GmbH US Patent | Assay Description The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,... | US Patent US8598206 (2013) BindingDB Entry DOI: 10.7270/Q25T3J5F | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM108096 (US8598206, Table 6, 5) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 5 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
The Medicines Company (Leipzig) GmbH US Patent | Assay Description The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,... | US Patent US8598206 (2013) BindingDB Entry DOI: 10.7270/Q25T3J5F | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Factor XIIa (Homo sapiens (Human)) | BDBM108096 (US8598206, Table 6, 5) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 530 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
The Medicines Company (Leipzig) GmbH US Patent | Assay Description Inhibition of human alpha-FXIIa was determined by the method described in [0092]-[0098] using activated human alpha-Factor XII (activated Hageman Fac... | US Patent US8598206 (2013) BindingDB Entry DOI: 10.7270/Q25T3J5F | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vitamin K-dependent protein C (Homo sapiens (Human)) | BDBM108096 (US8598206, Table 6, 5) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 1.20E+3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
The Medicines Company (Leipzig) GmbH US Patent | Assay Description Inhibition of human aPC was determined by the method described in [0092]-[0098] using human activated protein C from Enzyme Research Laboratories at ... | US Patent US8598206 (2013) BindingDB Entry DOI: 10.7270/Q25T3J5F | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Coagulation factor XI (Homo sapiens (Human)) | BDBM108096 (US8598206, Table 6, 5) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 1.40E+3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
The Medicines Company (Leipzig) GmbH US Patent | Assay Description Inhibition of human FXIa was determined by the method described in [0092]-[0098] using activated human Factor XI from Enzyme Research Laboratories at... | US Patent US8598206 (2013) BindingDB Entry DOI: 10.7270/Q25T3J5F | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Coagulation factor X (Homo sapiens (Human)) | BDBM108096 (US8598206, Table 6, 5) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 1.90E+3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
The Medicines Company (Leipzig) GmbH US Patent | Assay Description Inhibition of human FXa was determined by the method described in [0092]-[0098] using activated human Factor X from Enzyme Research Laboratories at 5... | US Patent US8598206 (2013) BindingDB Entry DOI: 10.7270/Q25T3J5F | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM108096 (US8598206, Table 6, 5) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 4.80E+3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
The Medicines Company (Leipzig) GmbH US Patent | Assay Description Inhibition of human t-PA was determined by the method described in [0092]-[0098] using recombinant human tissue-type plasminogen activator (Actilyse&... | US Patent US8598206 (2013) BindingDB Entry DOI: 10.7270/Q25T3J5F | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Transcription initiation factor IIA (Homo sapiens (Human)) | BDBM108096 (US8598206, Table 6, 5) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 8.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
The Medicines Company (Leipzig) GmbH US Patent | Assay Description Inhibition of human FIIa was determined by the method described in [0092]-[0098] using human alpha-thrombin from Enzyme Research Laboratories at 0.1 ... | US Patent US8598206 (2013) BindingDB Entry DOI: 10.7270/Q25T3J5F | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM108096 (US8598206, Table 6, 5) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | >2.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
The Medicines Company (Leipzig) GmbH US Patent | Assay Description Inhibition of human t-PA was determined by the method described in [0092]-[0098] using recombinant human tissue-type plasminogen activator (Actilyse&... | US Patent US8598206 (2013) BindingDB Entry DOI: 10.7270/Q25T3J5F | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement C1s (Homo sapiens (Human)) | BDBM108096 (US8598206, Table 6, 5) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | >2.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
The Medicines Company (Leipzig) GmbH US Patent | Assay Description Inhibition of human C1s was determined by the method described in [0092]-[0098] using native human activated C1s complement component from Calbioche... | US Patent US8598206 (2013) BindingDB Entry DOI: 10.7270/Q25T3J5F | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement C1r subcomponent (Homo sapiens (Human)) | BDBM108096 (US8598206, Table 6, 5) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | >4.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
The Medicines Company (Leipzig) GmbH US Patent | Assay Description Inhibition of human C1r was determined by the method described in [0092]-[0098] using native human activated C1r complement component from Calbiochem... | US Patent US8598206 (2013) BindingDB Entry DOI: 10.7270/Q25T3J5F | |||||||||||
More data for this Ligand-Target Pair |